Coronavirus / COVID

Evidence for using antibody-rich convalescent plasma in early, outpatient treatment of COVID-19 is described as "solid."

Breastfeeding babies safely receive COVID-19-neutralizing antibodies from their mRNA-vaccinated mothers.

New data suggests an additional “booster” dose of an mRNA COVID-19 vaccine is no longer just recommended but required for protection against the infectious Omicron variant.

Vaccine hesitancy is a significant hurdle experienced in the US. In response to this, a team of researchers analyzed adults who reported a medical provider recommended the COVID-19 vaccine, studied vaccination status, and general attitudes.

A panel of doctors explains whether or not someone can get a different COVID-19 booster from their original vaccinations and how they compare.

After increased awareness soon after the emergence of COVID-19, fewer Americans see plight of people of color.

Experts discuss who is eligible for COVID-19 booster shots and the misinformation around COVID-19 vaccinations.

The Advisory Committee on Immunization Practices (ACIP) voted yes to a third shot of the Pfizer-BioNTech COVID-19 vaccine in this pediatric population.

The CDC recommends all pregnant women receive a COVID-19 vaccine, finding vaccination does not increase risk of preterm birth or small-for-gestational-age at birth.

A pregnant woman is reported to be the country’s first person to be infected simultaneously with COVID-19 and influenza.

A new study found states that offered monetary prizes to randomly selected vaccinated persons did not have significant increases in vaccine uptake.

Novavax’s COVID-19 vaccine demonstrated 90.4% efficacy in a phase 3 trial with no moderate or severe cases reported among participants in the treatment group.

The country says one city hospital’s data shows a decrease in severity and mortality during this latest variant's outbreak.

The FDA now recommends Americans 12 years and older receive COVID-19 booster shots. Additionally, they moved to shorten the time in between the second and third dose from 6 months to 5 for Pfizer-BioNTech recipients.

Angela Rasmussen, PhD, and Donald Alcendor, PhD have a conversation on the recent expansion of COVID-19 booster shot usage in eligible populations.

Immigrant communities may be more hesitant to disclose personal health information due to fears of bullying or deportation, a new study finds.

Key opinion leaders debate on the necessity of COVID-19 booster shots.

Investigators in the United Kingdom showed a Pfizer-BioNTech booster dose increases neutralizing antibodies in a laboratory setting, and Omicron might not be as damaging to the lungs as previous variants.

The fast-moving Omicron variant demonstrates a high transmissibility, but not as significant a hospitalization rate or mortality.

COVID-19 patients who underwent prior weight-loss surgery were significantly less likely to experience severe disease outcomes.

The US is on track to reach new records for 7-day average cases, though death rates remain lower.

A phase 3 trial shows one dose is 91.7 % effective against severe disease.

The oral antiviral therapy proceeds the first indication for the drug class by just a day; the US will now have multiple pills to treat COVID-19.

This is the first pill to treat COVID-19 in trying to prevent progression to severe disease and possible hospitalization.

COVID-19 patients were not at increased risk of Clostridium difficile infection. However, those already infected with C diff were more likely to experience severe outcomes.

A study of mRNA vaccination in older people and people with comorbidities found vaccine efficacy of 69% against COVID-19 infection and 86% against death.

The administration is going to buy 500 million at-home rapid COVID-19 tests, and make them available to Americans. They also plan to use federal resources to provide pop-up clinics and get more pharmacists involved in vaccinations.

Here’s where you should sit on the bus to avoid COVID-19 droplets.

Less than 3 weeks after it was first reported, Omicron becomes the dominant COVID-19 variant in the US.

In the age of COVID-19, providers caring for patients with emerging diseases do not rely entirely on clinical guidelines, but also consult online resources that are updated more frequently. This needed integration helps providers adapt to the best-available evidence into bedside care when guidance is lacking.